Natalia Reixach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6165000/publications.pdf

Version: 2024-02-01

304743 395702 2,136 32 22 33 h-index citations g-index papers 33 33 33 2808 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 2817-2822.	7.1	336
2	Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of $A\hat{l}^2$ toxicity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2681-2686.	7.1	245
3	Transthyretin: the servant of many masters. Cellular and Molecular Life Sciences, 2009, 66, 3095-3101.	5.4	164
4	Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 2016, 7, 10787.	12.8	139
5	AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9992-9997.	7.1	120
6	Neuronal Production of Transthyretin in Human and Murine Alzheimer's Disease: Is It Protective?. Journal of Neuroscience, 2011, 31, 12483-12490.	3.6	105
7	Age-Related Oxidative Modifications of Transthyretin Modulate Its Amyloidogenicity. Biochemistry, 2013, 52, 1913-1926.	2.5	95
8	Sulfated Glycosaminoglycans Accelerate Transthyretin Amyloidogenesis by Quaternary Structural Conversion. Biochemistry, 2011, 50, 1001-1015.	2.5	89
9	Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochemical and Biophysical Research Communications, 2011, 410, 707-713.	2.1	85
10	Poly-(L-alanine) expansions form core \hat{l}^2 -sheets that nucleate amyloid assembly. Proteins: Structure, Function and Bioinformatics, 2005, 61, 579-589.	2.6	80
11	Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma. Nature Chemical Biology, 2010, 6, 133-139.	8.0	74
12	A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity. Journal of the American Chemical Society, 2010, 132, 1359-1370.	13.7	67
13	Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity. Science Translational Medicine, 2011, 3, 97ra81.	12.4	61
14	Human-Murine Transthyretin Heterotetramers Are Kinetically Stable and Non-amyloidogenic. Journal of Biological Chemistry, 2008, 283, 2098-2107.	3.4	48
15	The Systemic Amyloid Precursor Transthyretin (TTR) Behaves as a Neuronal Stress Protein Regulated by HSF1 in SH-SY5Y Human Neuroblastoma Cells and APP23 Alzheimer's Disease Model Mice. Journal of Neuroscience, 2014, 34, 7253-7265.	3.6	47
16	Oxidation inhibits amyloid fibril formation of transthyretin. FEBS Journal, 2006, 273, 5400-5406.	4.7	41
17	Transthyretin Deposition in Articular Cartilage: A Novel Mechanism in the Pathogenesis of Osteoarthritis. Arthritis and Rheumatology, 2015, 67, 2097-2107.	5.6	40
18	Inhibition of \hat{l}^2 -Amyloid-Induced Neurotoxicity by Imidazopyridoindoles Derived from a Synthetic Combinatorial Library. Journal of Structural Biology, 2000, 130, 247-258.	2.8	36

#	Article	IF	CITATIONS
19	Cell based screening of inhibitors of transthyretin aggregation. Biochemical and Biophysical Research Communications, 2006, 348, 889-897.	2.1	36
20	New ecdysteroids from Polypodium vulgare. Tetrahedron, 1994, 50, 7247-7252.	1.9	31
21	Quantification of Quaternary Structure Stability in Aggregation-Prone Proteins under Physiological Conditions: The Transthyretin Case. Biochemistry, 2014, 53, 6496-6510.	2.5	28
22	<i>In vivo</i> stabilization of mutant human transthyretin in transgenic mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 227-236.	3.0	27
23	Transthyretin deposition promotes progression of osteoarthritis. Aging Cell, 2017, 16, 1313-1322.	6.7	22
24	Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage. Bioscience Reports, 2015, 35, .	2.4	21
25	Biosynthesis of ecdysteroids in in vitro prothalli cultures of Polypodium vulgare. Phytochemistry, 1996, 43, 597-602.	2.9	19
26	The pathogenesis of transthyretin tissue deposition: lessons from transgenic mice. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 2-6.	3.0	17
27	Biotransformations of putative phytoecdysteroid biosynthetic precursors in tissue cultures of Polypodium vulgare. FEBS Journal, 1999, 266, 608-615.	0.2	16
28	Mutasynthesis of a Potent Anticancer Sibiromycin Analogue. ACS Chemical Biology, 2012, 7, 973-977.	3.4	16
29	Phytoecdysteroid overproduction in Polypodium vulgare prothalli. Phytochemistry, 1997, 46, 1183-1187.	2.9	12
30	Formation of cytotoxic transthyretin is not dependent on inter-molecular disulphide bridges commonly found within the amyloid form. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2008, 15, 240-245.	3.0	10
31	Successful identification of novel agents to control infectious diseases from screening mixture-based peptide combinatorial libraries in complex cell-based bioassays. Biopolymers, 2003, 71, 103-116.	2.4	7
32	Correction to Mutasynthesis of a Potent Anticancer Sibiromycin Analogue. ACS Chemical Biology, 2014, 9, 1214-1214.	3.4	1